The Role of an Aggrecan 32mer Fragment in Post-Traumatic Osteoarthritis
Abstract
In this fifth reporting period, we extended the activity in the absence of the agreement with the University of Melbourne. We have a fully executed agreement on file now (in place since December 2020). We have received a new plate reader at Rush (Perkin Elmer), necessary for continuing the project (arrived December 2020). While the administrative transfer was ongoing (and delayed due to the pandemic lockdown), we have tested existing mouse sera for the levels of the aggrecan 32-mer fragment. We have found that these old sera were no longer usable (likely due to instability of the 32-mer), and we will therefore conduct new experiments to generate sera for biomarker development. Specifically, we will validate the use of plasma 32mer levels as markers for osteoarthritis (pain) in mice at different time points after DMM surgery, and this in wildtype as well as Chloe mice (as negative controls). In addition, we will continue to validate the assay in existing human sera.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1126817
Entities
People
- Anne-marie Malfait
Organizations
- University of Melbourne